Rodman & Renshaw

The share price of American Superconductor Corporation (NASDAQ: AMSC) have appreciated 25.76 percent over the past month, from $4.09 on December 15. Rodman & Renshaw’s Amit Dayal has initiated coverage of the company with a Buy rating and price target of $10. Dayal believes that...

In a report published Tuesday, Rodman & Renshaw analyst Kevin Dede upgraded the rating on Towerstream Corporation (NASDAQ: TWER) to Buy, while initiating a price target of $3. Analyst Kevin Dede said that the company's "revenue tide" could change in view of new contracts and the "potential...

In a report published Thursday, Rodman & Renshaw analyst Amit Dayal initiated coverage of Digital Ally, Inc. (NASDAQ: DGLY) with a Buy rating and $24 price target. The company has been able to achieve an industry leading position through its consistent innovations. The spend on security system...

Rodman & Renshaw initiated coverage on Digital Ally, Inc. (NASDAQ: DGLY) with a Buy rating. The target price for Digital Ally is set to $24. Digital Ally shares have gained 303.57 percent over the past 52 weeks, while the S&P 500 index has surged 7.19 percent in the same period. Digital...

Rodman & Renshaw reduced its rating on Zalicus (NASDAQ: ZLCS) from Market Outperform to Market Perform and suspended its previous $5 price target. Rodman & Renshaw noted, "Yesterday, Zalicus (ZLCS) announced that Synavive failed to demonstrate clinically meaningful benefit compared to its...

Rodman & Renshaw initiated its coverage on CytRx Corporation (NASDAQ: CYTR) with a Market Outperform and a $7 price target. Rodman & Renshaw commented, "CytRx is a high-risk, high-reward play in the microcap oncology space. CytRx is developing aldoxorubicin (INNO-206), a tumor-targeted...

Rodman & Renshaw raised its rating on Catalyst Pharmaceuticals Partners (NASDAQ: CPRX) and announced a price target of $3.70 based on the current risk to reward outlook for the company. Rodman & Renshaw commented, "While it is our view that the risk-reward profile of CPRX shares is...

Rodman & Renshaw reiterated its Outperform rating on Pharmacyclics (NASDAQ: PCYC) and increased its price target to $75 a share. Rodman & Renshaw commented, "Pharmacyclics announced this morning that its Phase II trial, SPARK, evaluating ibrutinib in Mantle Cell Lymphoma (MCL) had...

Rodman & Renshaw Reiterated a Market Perform rating on Ariad Pharmaceuticals (NASDAQ: ARIA) and raised its price target to $26. Rodman & Renshaw commented, “ARIA also noted in today's release that it still intends to submit a marketing authorization application (MAA) for ponatinib to the...

Rodman & Renshaw maintained an Outperform rating on Alynlam Pharmaceuticals (NASDAQ: ALNY) and a $22 price target. Rodman & Renshaw commented, “We view today's news as yet another example in which management has monetized its RNAi platform to produce value for shareholders. In our...

Rodman & Renshaw reiterated an Outperform rating on Cytokinetics (NASDAQ: CYTK) and a target price of $2. Rodman & Renshaw wrote, “We expect management to provide further details on omecamtiv mecarbil's planned Phase II trials with oral formulations. Management announced last week that the...

In a report published Wednesday, Rodman & Renshaw reiterated its Market Outperform rating on Vivus (NASDAQ: VVUS), and raised its price target to $52.00, related to the recent approval of the diet drug Qsymia. Rodman & Renshaw noted, “We view the Qsymia label as a positive and in-line with...

Rodman & Renshaw has published a research report on Alnylam Pharmaceuticals (NASDAQ: ALNY) after the company reported Phase I data for ALN-TTR02 that showed robust knockdown of the transthyretin (TTR) gene. In the report, Rodman & Renshaw writes, "Recall, this trial and the previous Phase...

Rodman & Renshaw maintained its Celgene (NASDAQ: CELG) Market Perform rating and $76 price target in a research report published today on news of published material relevant to IDH1 mutation and AML in the scientific journal Nature. In the report, Rodman & Renshaw stated, "We continue to...

Rodman & Renshaw reiterates its Market Outperform rating on Ventrus Biosciences (NASDAQ: VTUS) and reduces its price target from $25 to $11. Rodman & Renshaw comments, "VTUS announced this morning that its Phase III trial of VEN 309 (iferanserin) in patients with hemorrhoidal disease...